Navigation Links
Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
Date:12/22/2009

s first-line therapy for weight management."

Phase 3 Program Overview

BLOOM and BLOSSOM comprise the pivotal Phase 3 program and are the basis of the lorcaserin NDA submission. These double-blind, randomized, placebo-controlled trials evaluated 10 mg of lorcaserin dosed once or twice daily versus placebo for up to two years in obese patients, Body Mass Index (BMI) 30 to 45, with or without co-morbid conditions and overweight patients, BMI 27 to 29.9, with at least one co-morbid condition. Positive results from the pivotal program were presented at the 69th Scientific Sessions of the American Diabetes Association and the 27th Annual Scientific Meeting of The Obesity Society.

In addition to the pivotal program, Arena is evaluating lorcaserin in obese and overweight patients with type 2 diabetes in its BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial. BLOOM-DM is planned as a supplement to the NDA.

About Lorcaserin

Lorcaserin is a novel single agent that represents the first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area involved in the control of appetite and metabolism. Stimulation of this receptor is strongly associated with feeding behavior and satiety. Arena has patents that cover lorcaserin in the US and other jurisdictions, which in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Integrated Silicon Solution, Inc. (Nasdaq: ... IC solutions, today announced that it will host its ... 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to ... third quarter ended June 30, 2014. To ... 6:50 a.m. Pacific time on July 24, 2014.  The ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... N.C. , May 12 Cogdell Spencer Inc. (NYSE: ... of 6,500,000 shares of common stock.  Cogdell Spencer also plans to grant ... of common stock. Citi and KeyBanc Capital Markets are acting as joint ... The Company ...
... WASHINGTON , May 12 The New England Journal of ... Pharmaceutical Companies." Some of the whistleblower cases discussed in the report were brought ... DC , and San Francisco . Phillips & Cohen has specialized in ... , , ...
Cached Medicine Technology:Cogdell Spencer Announces Commencement of Common Stock Offering 2Cogdell Spencer Announces Commencement of Common Stock Offering 3Whistleblower Lawyers Comment on New England Journal of Medicine Study 2Whistleblower Lawyers Comment on New England Journal of Medicine Study 3
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, 2014 (HealthDay ... thought to be cured by immediate and aggressive drug treatment ... AIDS-causing virus in her bloodstream, disappointed federal officials announced Thursday ... remained virus-free even though she stopped taking HIV medications when ... would open the door to a functional cure for all ...
(Date:7/11/2014)... UK (PRWEB) July 11, 2014 Microbiology ... of the in-vitro diagnostics industry, which is expected to ... ten years. The sector owes its growth to the ... to people’s health worldwide and a major factor leading ... technologies, threat of bio-terrorism, and a broader availability of ...
(Date:7/11/2014)... 11, 2014 The report, “Specialty ... Applications & Geography - 2018,” defines and segments ... with an analysis and forecast of the volumes ... fibers (Para aramids, meta aramids, UHMW Polyethylene, carbon ... PPS fiber, PBI fiber, PBO fiber, and liquid ...
(Date:7/11/2014)... Datalogic brings a new and innovative ... wide. With their new Gryphon GD4400 and ... the devastating MRSA, which claimed 5,500 lives, becomes more ... 2D and the Gryphon GM4400-HC 2D readers can scan ... read barcodes off of troublesome LCD monitors, smartphones, and ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... least $50 billion in fuel costs now ... The current GHG standards are ... taken it upon themselves to install new ... , 1.    Idle reduction technologies , 2.    Efficient driveline ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3
... County residents will have the opportunity to witness a special, ... traditional lighting of the Saugatuck River Bridge at dusk. Those ... the door, will enjoy cuisine and drink from some of ... chance to participate in a silent auction that includes items ...
... VIEW, Calif., July 7 ... has closed its acquisition of the Managed Security Services ... VeriSign is the trusted provider of Internet infrastructure services ... strengthens its leadership position as a global, pure-play security ...
... , MORTON GROVE, Ill., July 7 Lifeway Foods, Inc. (Nasdaq: ... a provider of other natural and organic dairy products, invites you ... throws out the first pitch before the Chicago Cubs take on ... , At this official "Lifeway Day with the Cubs," the local ...
... July 7 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: ... and supplier of pharmaceutical,products and medical nutrients addressing a ... has commenced the full implementation of the,new rural cooperative ... Since the beginning of April, Biostar has deployed ...
... Web reports by states and municipalities , TUESDAY, July ... the United States get mixed marks for their use of ... outbreak, a new study shows. , After the U.S. government ... state health departments posted some information about the H1N1 outbreak ...
... the director of Developmental Care and Follow-up at Texas Children,s ... Medicine , has been appointed chair of the American Academy ... assumed the role on July 1st and will oversee the ... succeed Ann Stark, M.D., FAAP, chief of Neonatology at Texas ...
Cached Medicine News:Health News:Al's Angels' 'Angels in July' Saugatuck River Bridge Lighting to Benefit Children in Need 2Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 2Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 3Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 4Health News:Giant Bugs Invade Wrigley Field 2Health News:Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan 2Health News:Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan 3Health News:Mixed Marks for Swine Flu Updates 2Health News:The American Academy of Pediatrics Names Lu-Ann Papile, M.D., FAAP, as Chair of the Fetus and Newborn Committee 2Health News:The American Academy of Pediatrics Names Lu-Ann Papile, M.D., FAAP, as Chair of the Fetus and Newborn Committee 3
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
... a new level of immunodiagnostic productivity. Optimal ... any laboratory automation system. No-pause loading of ... the only immunoassay system with this capability. ... runs without any additional setup. Continuous sample ...
... and medium volume laboratories, as well as ... the speed, simplicity and flexibility needed to ... powerful, the Elecsys 1010 system enables operators ... to routine testing without sacrificing ease of ...
Medicine Products: